OncoMatch/Clinical Trials/NCT05584761
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
Is NCT05584761 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies unrelated umbilical cord blood for myelodysplastic syndromes.
Treatment: unrelated umbilical cord blood — This research is being done to study the efficacy and safety of unrelated umbilical cord blood stem cell microtransplantation combined with azacitidine(AZA) based treatment for advanced myelodysplastic syndromes(MDS), Chronic myelomonocytic leukemia-2(CMML-2) and secondary acute myeloid leukemia(sAML). The study protocol involved unrelated umbilical cord blood stem cell combined with azacitidine based treatment, which including azacitidine alone and azacitidine plus a targeted agent or chemotherapy agent.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Biomarker criteria
Excluded: ABL1 fusion
Excluded: BCR fusion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
serum creatinine <=150umol/L; eGFR >=30mL/min/1.73m2
Liver function
ALT, AST and serum bilirubin <=2x ULN
Cardiac function
myocardial enzyme <2x ULN (of the same age); LVEF >=50% by echocardiogram
ALT, AST and serum bilirubin <=2 upper limit of normal (ULN), serum creatinine <=150umol/L, myocardial enzyme <2xULN (of the same age); Left ventricularinjection fraction(LVEF)>=50% by echocardiogram; Estimated glomerular filtration rate (eGFR) ≥30mL/min/1.73m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify